Pediatrix Medical Group, Inc. (NYSE:MD) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been assigned a consensus recommendation of “Hold” from the six research firms that are currently covering the stock, MarketBeat reports. Five investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $21.00.

Several equities analysts recently issued reports on MD shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Zacks Research lowered shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. UBS Group boosted their target price on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Finally, Truist Financial increased their price target on Pediatrix Medical Group from $17.00 to $24.00 and gave the stock a “hold” rating in a research report on Monday, November 10th.

Insider Activity at Pediatrix Medical Group

In related news, CEO Mark S. Ordan sold 23,000 shares of Pediatrix Medical Group stock in a transaction dated Monday, December 15th. The stock was sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the transaction, the chief executive officer directly owned 302,805 shares of the company’s stock, valued at $6,785,860.05. The trade was a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Pediatrix Medical Group

Large investors have recently made changes to their positions in the company. Royal Bank of Canada increased its position in Pediatrix Medical Group by 23.8% in the first quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock worth $320,000 after purchasing an additional 4,247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Pediatrix Medical Group by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock valued at $743,000 after purchasing an additional 2,251 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Pediatrix Medical Group by 4.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock worth $3,891,000 after buying an additional 12,171 shares during the period. Allianz Asset Management GmbH raised its stake in shares of Pediatrix Medical Group by 159.1% during the second quarter. Allianz Asset Management GmbH now owns 61,412 shares of the company’s stock worth $881,000 after buying an additional 37,712 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in shares of Pediatrix Medical Group by 1.6% during the second quarter. Nordea Investment Management AB now owns 268,219 shares of the company’s stock worth $3,793,000 after buying an additional 4,159 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock opened at $21.48 on Thursday. The firm has a market capitalization of $1.84 billion, a P/E ratio of 11.31 and a beta of 0.76. The stock has a fifty day moving average price of $21.68 and a two-hundred day moving average price of $19.43. Pediatrix Medical Group has a 52-week low of $11.84 and a 52-week high of $24.99. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.83 and a quick ratio of 1.83.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.